Effect of Anapsos® in a murine model of experimental trichomoniasis

• Published in: Parasite (Paris) Vol. 10; no. 4; pp. 303 - 308
• Main Authors: Nogal-Ruiz, J.J., Gómez-Barrio, A., Escario, J.A., Martínez-Fernández, A.R.
• Format: Journal Article
• Language: English
• Published: Paris EDP Sciences 01.12.2003; Princeps
• Subjects: Adjuvants, Immunologic - administration & dosage; Adjuvants, Immunologic - pharmacology; Anapsos; Animals; Azathioprine - pharmacology; Biological and medical sciences; cyclophosphamide; Cyclophosphamide - pharmacology; Disease Models, Animal; Disease Susceptibility; Dose-Response Relationship, Drug; Female; FK-506; General pharmacology; glycophosphopeptical; Glycosides - administration & dosage; Glycosides - pharmacology; Humans; immunomodulation; Immunosuppressive Agents - pharmacology; Male; Medical sciences; Mice; Pharmacognosy. Homeopathy. Health food; Pharmacology. Drug treatments; Plant Extracts - pharmacology; Polypodium - chemistry; Polypodium leucotomos; Random Allocation; Tacrolimus - pharmacology; Trichomonas Infections - immunology; Trichomonas Infections - mortality; Trichomonas Infections - pathology; Trichomonas vaginalis; Trichomonas vaginalis - growth & development; Trichomonas vaginalis - immunology; Trichomonas vaginalis - pathogenicity; Trichomonas Vaginitis - immunology; Trichomonas Vaginitis - parasitology; Trichomonas Vaginitis - pathology; Trichomonas vaginalis; Host parasite relation; Animal model; Protozoal disease; Trichomonadida; Immunity; Tissue extract; Filicineae; Protozoa; Immune response; Immunomodulation; Pharmacognosy; Rodentia; Host; Parasitosis; Pteridophyta; Biological activity; Infection; Vertebrata; Immunostimulant agent; Experimental disease; Mammalia; Mouse; Trichomoniasis; Plant origin; Parasitism
• ISSN: 1252-607X; 1776-1042
• DOI: 10.1051/parasite/2003104303

Immunomodulator effect of Anapsos® (Polypodium leucotomos extract) in NMRI (US Naval Medical Research Institute) outbred mice infected by the intraperitoneal route with 107 Trichomonas vaginalis has been tested. Gross histopathologic changes in abdominal organs and mortality rate, as a consequence of the pathogenicity of the protozoa and the immune response of the host, were evaluated. Among the different treatment regimes assayed, Anapsos® at doses of 20 mg/Kg/day administered for 10 days before infection decreases the parasite pathogenicity index (PI) in the treated animals when compared to those of the untreated control group. The immunosuppresor treatments with azathioprine (100 mg/Kg/day x 1), cyclophosphamide (100 mg/Kg/day x 1), and FK-506 (10 mg/Kg/day x 10) significantly decreased the PI, while an immunostimulant treatment with glycophosphopeptical (13 mg/Kg/day x 10) increased it. These assays have shown the usefulness of the murine model of experimental trichomoniasis for the study of immunomodulator activity of natural or synthetic drugs. La modulation de la réponse immunitaire dans un modèle de pathogénie expérimentale de Trichomonas vaginalis (107 trichomonadides inoculés dans le péritoine) chez la souris NMRI a été examinée par l'étude des changements histopathologiques sur les organes abdominaux et la mortalité après le traitement avec un extrait de Polypodium leucotomos (Anapsos®). Parmi les différents types de traitement analysés, l'Anapsos® (20 mg/Kg/jour administrés pendant 10 jours avant I'infestation) induit une réduction quantitative des lésions abdominales évaluées chez les animaux traités par comparaison aux non traités. D'autre part, les traitements immunosuppresseurs avec Tazathioprine (100 mg/Kg/jour x 1), le cyclophosphamide (100 mg/Kg/jour x 1), et le FK-506 (10 mg/Kg/jour x 10) diminuent de manière significative la pathogenicité de T. vaginalis (PI), tandis que le traitement avec glycophosphopeptical (13 mg/Kg/jour x 10), un agent immunostimulant, l'augmente. Les essais effectués ont montré l'utilité d'un modèle de trichomoniasis expérimental pour l'évaluation de l'immunomodulation des drogues naturelles ou synthétiques.